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Targeting melanoma’s MCL1 bias unleashes the
apoptotic potential of BRAF and ERK1/2
pathway inhibitors
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BRAF and MEK1/2 inhibitors are effective in melanoma but resistance inevitably develops.
Despite increasing the abundance of pro-apoptotic BIM and BMF, ERK1/2 pathway inhibition
is predominantly cytostatic, reﬂecting residual pro-survival BCL2 family activity. Here, we
show that uniquely low BCL-XL expression in melanoma biases the pro-survival pool towards
MCL1. Consequently, BRAF or MEK1/2 inhibitors are synthetic lethal with the MCL1 inhibitor
AZD5991, driving profound tumour cell death that requires BAK/BAX, BIM and BMF, and
inhibiting tumour growth in vivo. Combination of ERK1/2 pathway inhibitors with BCL2/BCL-
w/BCL-XL inhibitors is stronger in CRC, correlating with a low MCL1:BCL-XL ratio; indeed the
MCL1:BCL-XL ratio is predictive of ERK1/2 pathway inhibitor synergy with MCL1 or BCL2/
BCL-w/BCL-XL inhibitors. Finally, AZD5991 delays acquired BRAFi/MEKi resistance and
enhances the efﬁcacy of an ERK1/2 inhibitor in a model of acquired BRAFi+MEKi resistance.
Thus combining ERK1/2 pathway inhibitors with MCL1 antagonists in melanoma could
improve therapeutic index and patient outcomes.
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BRAF inhibitors (BRAFi, vemurafenib and dabrafenib) andMEK1/2 inhibitors (MEKi, trametinib) improve the out-comes of patients with BRAFV600E/K-mutant melanoma1–3.
However, disease relapse typically occurs due to acquired resis-
tance that reinstates ERK1/2 signalling4,5. Although combining
BRAFi and MEKi improves responses6,7, acquired resistance and
disease relapse are only delayed and again typically arise through
reactivation of ERK1/24,5. Thus, strategies are required that boost
the primary efﬁcacy of BRAFi and MEKi to delay or prevent the
emergence of resistance.
The cell intrinsic apoptotic pathway is regulated by BCL2 family
proteins, which are frequently deregulated in cancer, typically
through aberrant expression, activity or deregulation of oncogenic
signalling cascades. ERK1/2 can promote cell survival in BRAF-
or KRAS-mutant tumour cells8 by increasing expression of pro-
survival BCL2 proteins. ERK1/2 stabilise MCL1 through phos-
phorylation of T163 and indirectly through RSK-mediated inhibi-
tion of GSK39. ERK1/2 signalling also drives transcription ofMCL1,
BCL2 and BCL-XL8. In addition, ERK1/2 signalling inhibits the pro-
apoptotic BH3-only proteins BIM, BMF, PUMA and BAD. ERK1/2
directly phosphorylate BIM, targeting it for ubiquitination and
proteasomal degradation10. ERK1/2 signalling also represses BMF
protein expression11, and promotes BAD inactivation through
MSK/RSK-catalysed phosphorylation and sequestration by 14-3-3
proteins8. Although ERK1/2 have been proposed to regulate BIK in
a manner analogous to BIM, this is disputed12,13. ERK1/2 signalling
also represses BIM and PUMA transcription by destabilising
FOXO3A14–17. As a result, inhibition of ERK1/2 signalling in
tumour cells invariably promotes the expression of pro-apoptotic
BIM, BMF and/or PUMA11. Despite this, apoptotic responses to
ERK1/2 pathway inhibitors are typically weak because of residual
activity of pro-survival BCL2 proteins.
Among the agents developed to inhibit pro-survival proteins
and drive tumour cell apoptosis18, drugs that mimic the BH3
domains of BH3-only proteins (BH3-mimetics) are the most
advanced. Venetoclax (ABT-199), a BCL2-selective inhibitor, has
been approved for clinical use. Navitoclax (ABT-263) and
AZD4320 target BCL2, BCL-w and BCL-XL but not MCL1 or
A119–22. AZD4320 has nanomolar afﬁnity for BCL2 and BCL-XL
and physicochemical properties suitable for intravenous admin-
istration, which may avoid toxicities observed with oral admin-
istration of navitoclax21,23,24. BCL2/BCL-w/BCL-XL inhibitors are
showing promise in haematological malignancies such as chronic
lymphocytic leukaemia (CLL), but will require combination to be
effective in solid tumours. Indeed, ERK1/2 pathway inhibitors
combine with navitoclax, or the close analogue ABT-737, to
induce colorectal cancer (CRC) apoptosis and tumour regression
in vivo11,25,26. This combination may also be effective in non-
small cell lung cancer (NSCLC) and pancreatic tumours; however,
we and others have noted more limited synergy between ERK1/2
pathway inhibitors and navitoclax/ABT-737 in melanoma11,26–28.
BCL-XL and MCL1 are the major pro-survival proteins in solid
tumours (Cancer Cell Line Encyclopaedia (CCLE; https://portals.
broadinstitute.org/ccle) and The Cancer Genome Atlas (TCGA;
https://cancergenome.nih.gov/)), but development of MCL1
inhibitors (MCL1i) has lagged behind that of BCL2/BCL-w/BCL-
XL inhibitors due to challenges associated with targeting the
MCL1 BH3-binding groove8,29,30. However, since potent and
selective MCL1i are now in clinical development, including
S6384531, AMG 17632 and AZD599133, it is imperative to identify
drug combinations and disease stratiﬁcation criteria to maximise
their impact.
Here, we show that the pro-survival BCL2 family pool is biased
towards MCL1 in melanoma compared to CRC, NSCLC and
pancreatic tumour lineages, due to low BCL-XL expression. Thus,
MCL1 is critical in restraining pro-apoptotic BH3-only proteins
induced by ERK1/2 inhibition in melanoma. Consequently, com-
bined inhibition of ERK1/2 signalling and MCL1 is synthetic
lethal, inducing profound, synergistic BAK/BAX-, BIM- and BMF-
dependent apoptosis and tumour regression. Finally, combining
ERKi and MCL1i overcomes acquired resistance to combined
BRAFi+MEKi. Thus, exploiting speciﬁc inhibition of ERK1/2 sig-
nalling and apoptotic priming in BRAF-mutant cells coupled with
the pro-survival bias towards MCL1 could afford a large therapeutic
window and further improve patient outcomes in melanoma.
Results
The melanoma pro-survival BCL2 family pool is MCL1 biased.
We ﬁrst examined RNA-sequencing (RNA-seq) data available in
the CCLE for transcripts encoding pro-survival BCL2 proteins34.
While MCL1 expression in the CCLE data set was broadly similar
in CRC and melanoma cells, and slightly higher in NSCLC and
pancreatic, levels of BCL2L1 (encoding BCL-XL) were strikingly
lower in melanoma relative to the other lineages (Fig. 1a, b).
Consequently, the MCL1:BCL-XL mRNA ratio, encoding the
major pro-survival proteins in solid tumours, was two- to four-
fold higher in melanoma than in the other lineages (Fig. 1c).
Indeed, of all the tumour lineages in the CCLE, melanoma
exhibited one of the highest median MCL1:BCL-XL mRNA ratios
(Supplementary Fig. 1a). Notably autonomic ganglia tumour cells
which, like melanocytes, have neural crest developmental origin
also exhibited a high MCL1:BCL-XL ratio. While BCL2 expression
was higher in melanoma, BCL2 mRNA levels (RNA-seq read
number) were very low in each lineage relative toMCL1 and BCL-
XL (Supplementary Fig. 1b). BCL2L2 (encoding BCL-w) levels
were similar in each lineage (Supplementary Fig. 1c) and BCL2A1
(encoding A1/BFL1), a MITF target gene35, exhibited melanoma-
selective expression (Supplementary Fig. 1d). Similar observations
have been made in TCGA patient samples (https://cancergenome.
nih.gov/). We conﬁrmed these trends at the protein level in seven
melanoma and seven CRC cell lines (Fig. 1d, e). All melanoma
cell lines exhibited strikingly lower BCL-XL expression than the
CRC cell lines whereas MCL1 was, on the whole, marginally
higher in melanoma (Fig. 1d, e). BCL2 expression was markedly
elevated in melanoma (Fig. 1d and Supplementary Fig. 2a),
consistent with BCL2 being a MITF target gene36. BCL-w levels
were similar between CRC and melanoma (Fig. 1d and Supple-
mentary Fig. 2b). We failed to detect A1 protein expression using
a variety of commercially available antibodies, even in melanoma
cells with high BCL2A1 mRNA.
Next, we used recombinant protein standards (Supplementary
Fig. 2c, d) to absolutely quantify MCL1 and BCL-XL in 64 cell lines
(Supplementary Fig. 2e–h), and thereby determine the MCL1:BCL-
XL protein ratio (Fig. 1f–h). MCL1 levels were similar across the
four lineages but higher in melanoma (~20 vs. <14 fmol per μg total
cellular protein; Fig. 1f and Supplementary Fig. 2f). Consistent with
mRNA levels, BCL-XL protein was strikingly lower in melanoma
(Fig. 1g and Supplementary Fig. 2f) compared to CRC, NSCLC and
pancreatic lineages (median value of <4 fmol vs. >11 fmol per μg
total cellular protein). Consequently the MCL1:BCL-XL ratio was
substantially biased towards MCL1 in melanoma (Fig. 1h); the
median ratio was 5–6 in melanoma vs. ~1 in CRC and pancreatic
tumour cells, and ~2 in NSCLC (Fig. 1h). The same analysis in CRC
and melanoma patient-derived xenograft (PDX) samples (Fig. 1i–l)
demonstrated markedly low BCL-XL expression in melanoma
PDXs vs. CRC (Fig. 1i, k), whereas MCL1 expression was broadly
similar (Fig. 1i, j). Consequently, the MCL1:BCL-XL protein ratio
was ~5 times higher in melanoma (Fig. 1l). Thus, the ratio of the
two major pro-survival proteins in solid tumours, MCL1 and BCL-
XL, is substantially biased towards MCL1 in melanoma cell lines
and patient samples.
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BRAFi or MEKi combine with MCL1i to selectively kill mela-
noma cells. Combining BRAFi or MEKi with pan-BCL2/BCL-w/
BCL-XL inhibitors causes strong synergistic cell death of CRC,
NSCLC and pancreatic cells and tumour regressions11,25,26.
However, we and others observed more modest synergy in
melanoma11,26–28. This difference could be explained by the bias
towards MCL1 in melanoma (Fig. 1 and Supplementary Figs. 1 and
2). We therefore tested ERK1/2 pathway inhibitors in combination
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with the novel MCL1i AZD599133 using high-throughput combi-
nation assays (HTCA) in an 8 × 8 concentration matrix and
determining Loewe synergy scores in 12 melanoma and CRC cell
lines. These responses were compared to those with the BCL2/
BCL-w/BCL-XL inhibitor AZD4320, which has nanomolar afﬁnity
for these pro-survival proteins, similar to navitoclax21,23,24.
Combination of MEKis trametinib or selumetinib (AZD6244,
ARRY-142886) with AZD5991 or AZD4320 was performed in all
CRC and melanoma cell lines to allow comparison of BRAFMUT,
RASMUT or RAS/RAFWT cells (Supplementary Table 1); combi-
nations with the BRAFi vemurafenib (only effective in BRAFV600-
mutant cells) or ERK1/2 inhibitor SCH772984 were tested in
selected cell lines. Data from these combination assays are shown
in Fig. 2a–c and Supplementary Figs. 3–6 where trametinib, selu-
metinib or vemurafenib combined with AZD5991 to cause strong
cell death in BRAFV600E-mutant A375, SK-MEL-28, WM266-4,
A2058 or SK-MEL-5 melanoma cells. MEKis or ERKi, also com-
bined well with AZD5991 in NRAS-mutant MEL-JUSO, SK-MEL-
2, SK-MEL-30 and WM852 melanoma cells (Supplementary
Figs. 3–6). In these melanoma cells, ERK1/2 pathway inhibitors
typically combined less well with AZD4320 than AZD5991,
whereas trametinib or selumetinib combined better with AZD4320
than AZD5991 in HCT116 and HT29 CRC cells (Supplementary
Fig. 5). Loewe synergy score calculation for all 24 cell lines (Sup-
plementary Table 2) revealed that both AZD5991 and AZD4320-
synergised (score ≥ 5) with trametinib and selumetinib in the
majority of cell lines (Fig. 2d, e). However, synergy with AZD5991
was typically far stronger in melanoma: median synergy scores for
trametinib or selumetinib combined with AZD5991 were >3 times
higher in melanoma than CRC, whereas combination with
AZD4320 was more effective than with AZD5991 in CRC (>2-fold
higher median synergy score).
We conﬁrmed these high-throughput results in selected cell lines
by examining cell cycle proﬁles. Vemurafenib (Fig. 2f) or
selumetinib (Supplementary Fig. 7a) resulted in a strong G1 arrest
in BRAF-mutant A375 cells but only limited cell death (<10% sub-
G1 DNA fraction) at higher concentrations. 1 μM AZD5991 had
no effect on cell cycle or cell death; however, combination of
AZD5991 with 1 μM vemurafenib or selumetinib elicited 65–75%
cell death (Fig. 2f and Supplementary Fig. 7a). In A375 cells, 10 μM
AZD5991 had no effect on cell cycle proﬁle, whereas concentra-
tions as low as 100 nM combined with selumetinib to induce
substantial synergistic cell death (Supplementary Fig. 7b). Very
similar results were observed in NRASQ61K-mutant SK-MEL-30
melanoma cells (Supplementary Fig. 7c, d). Further experiments
focused on annexin V-positive, apoptotic cells. In A375 cells both
vemurafenib and selumetinib combined synergistically with
AZD5991 to drive ~80% apoptosis following 48 h treatment
(Fig. 2g, h); similar results were observed with vemurafenib in
BRAF-mutant WM266-4 (Supplementary Fig. 7e) and selumetinib
in NRAS-mutant SK-MEL-30 cells (Supplementary Fig. 7f). BRAFi
(vemurafenib), MEKi (selumetinib) or ERKi (SCH772984) com-
bined to kill BRAF-mutant A375 and WM266-4 cells in a caspase-
dependent fashion (Fig. 2i) but only selumetinib or SCH772984
were effective in NRASQ61K-mutant SK-MEL-30 cells, consistent
with vemurafenib efﬁcacy being conﬁned to BRAF-mutant tumour
cells. In contrast, and consistent with results from the HTCA
experiments, A375 (Fig. 2j, k) and SK-MEL-30 cells (Supplemen-
tary Fig. 7g, h) both exhibited markedly weaker apoptotic
responses when selumetinib was combined with the BCL2/BCL-
w/BCL-XL inhibitor AZD4320 rather than AZD5991.
The inverse was true for the CRC cell lines COLO205 and
SW620. While selumetinib and AZD5991 combined to induce
apoptosis in COLO205 cells (Emax ~ 45%), far stronger synergistic
apoptosis was apparent with AZD4320 (Emax ~ 80%) (Fig. 2l, m).
SW620 cells were an even more striking example: combination of
selumetinib with 10 μM AZD5991 resulted in <10% apoptosis,
whereas ~90% apoptosis was achieved when selumetinib was
combined with AZD4320 (Fig. 2n, o). Indeed, in COLO205 and
SW620, concentrations of AZD4320 >1 μM elicited considerable
apoptosis alone (Fig. 2m, o), suggesting a stronger dependency
upon BCL2, BCL-w and/or BCL-XL for basal viability in CRC.
Combination of navitoclax with selumetinib promoted only
modest apoptosis at near-identical potency and maximal response
as AZD4320 in A375 and SK-MEL-30 (Supplementary Fig. 7i, j),
consistent with AZD4320 and navitoclax having similar
pharmacology21,23,24.
To investigate the role of the individual pro-survival proteins
inhibited by AZD4320/navitoclax in melanoma, we used selective
inhibitors of BCL2 (venetoclax, ABT-199) and BCL-XL (A-
1155463)37. Selumetinib combined weakly with A-1155463 in
A375 or SK-MEL-30 (Fig. 2p, q) to induce a similar apoptotic
response as with AZD4320 or navitoclax (Fig. 2k and Supple-
mentary Fig. 7h–j). Despite higher levels of BCL2 in melanoma
relative to CRC (Fig. 1d and Supplementary Fig. 1b) venetoclax
monotherapy had no effect on viability and did not combine with
selumetinib to induce apoptosis, although venetoclax marginally
enhanced the combination effect of A-1155463 and selumetinib
in A375 cells (Fig. 2p and Supplementary Fig. 7k, l). Thus,
melanoma cells were not addicted to BCL2 for viability when the
ERK1/2 pathway was inhibited. BCL2 inhibition may, however,
slightly enhance the effect of BCL-XL inhibition when the ERK1/2
pathway is inhibited in some melanoma cells. These results
indicate that different tumour lineages exhibit selective
Fig. 1 Low BCL-XL expression in melanoma biases the pro-survival pool towards MCL1. a–c RNA-sequencing mRNA expression data obtained from the
Cancer Cell Line Encyclopaedia for MCL1 (a) BCL-XL (BCL2L1) (b) and MCL1:BCL-XL ratio (c) in colorectal cancer (CRC), melanoma, non-small cell lung
cancer (NSCLC) and pancreatic tumour cells. Expression values are reads per kilobase million (RPKM) and are presented on a log2 scale. Black lines
indicate median values. d, e Seven CRC (left) and seven melanoma (right) cell lines were cultured for 24 h before lysis and western blotting with the
indicated antibodies. Quantiﬁcation (e) of MCL1 and BCL-XL levels relative to A375 cells was performed by quantitative western blotting with ﬂuorescently
labelled secondary antibodies. f, g MCL1 (f) and BCL-XL (g) expression were quantiﬁed absolutely in CRC, melanoma, NSCLC and pancreatic tumour cell
lines using recombinant protein standards and quantitative western blotting with ﬂuorescently labelled secondary antibodies. Each point represents mean
expression in a cell line from three independent experiments and is expressed in fmol per µg of total cellular protein (fmol µg−1). Black lines indicate
median values. h Ratio of MCL1 to BCL-XL protein calculated from f and g, with black lines indicating median values. i Seven CRC (left) and seven
melanoma (right) patient-derived xenograft (PDX) tumours were homogenised in lysis buffer and western blotted with the indicated antibodies.
j, k Absolute quantiﬁcation of MCL1 (j) and BCL-XL (k) expression in CRC and melanoma PDX tumour samples using recombinant protein standards and
quantitative western blotting with ﬂuorescently labelled secondary antibodies. Each point represents mean expression in a cell line from at least ﬁve
technical replicates and is expressed in fmol per µg of total cellular protein (fmol µg−1). Black lines indicate median values. l Ratio of MCL1 to BCL-XL
protein calculated from (j) and (k), with black lines indicating median values. Results (e–h, j–l) are the mean of three or more independent experiments,
and error bars indicate SD. P≤ 0.0001 (****), P≤ 0.001 (***), P≤ 0.01 (**), P≤ 0.05 (*), ns (not signiﬁcant) as determined by Kruskal–Wallis and Dunn’s
multiple comparisons tests (a–c, f–h) or two-tailed Mann–Whitney test (j–l)
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dependencies upon distinct BCL2 proteins for survival, with
melanoma exhibiting a strong bias towards MCL1 and CRC an
apparent bias towards BCL-XL.
Combining vemurafenib or selumetinib with AZD5991 also
inhibited the clonogenic survival of A375 cells (Fig. 3a, b).
However, combined vemurafenib and AZD4320 or navitoclax did
not signiﬁcantly inhibit colony formation (Fig. 3c and Supple-
mentary Fig. 8a).
The striking synergy between ERK1/2 pathway inhibition and
AZD5991 in melanoma was also observed in vivo. While
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selumetinib moderately inhibited the growth of A375 tumour
xenografts, and AZD5991 had no effect, selumetinib+AZD5991
caused regression of established tumours and durable full growth
inhibition (Fig. 3d, e and Supplementary Fig. 8b, c). Given that
AZD5991 is cleared quickly from blood plasma, within 2–6 h33,
this efﬁcacy is particularly striking in the context of a once weekly
AZD5991 dosing schedule that likely results in MCL1 inhibition
for just a few hours per week. Throughout dosing there was little
change in mouse body mass indicating that these treatments were
well tolerated (Supplementary Fig. 8d).
We next examined BRAFV600E-mutant primary patient-
derived melanoma cells. Consistent with the results described
above, trametinib and AZD5991 combined to kill MEDI-MEL-10
and MEDI-MEL-07 primary melanoma cells (Fig. 4a–d), whereas
combination with AZD4320 or A-1155463 was far less effective
(Fig. 4e, f). Thus, dependency on MCL1 when the ERK1/2
Fig. 2 ERK1/2 pathway inhibitors combine with the MCL1 inhibitor AZD5991 to kill melanoma cells. a–c A375 (a), SK-MEL-28 (b) and WM266-4 (c) cells
were treated with the indicated concentrations of trametinib or vemurafenib in combination with AZD5991 for 5 days. The number of viable cells was
determined at the point of treatment (day 0) and at the end of the experiment using Sytox Green. One-hundred percent represents the number of viable
cells in the control wells at day 5, 0% is equivalent to the number of viable cells on day 0 and −100% indicates that no viable cells remained on day 5.
d, e Twelve melanoma and 12 colorectal cancer (CRC) cell lines were treated with trametinib (Tra) or selumetinib (Sel) and AZD5991 or AZD4320 in an
8 × 8 concentration matrix for 5 days. Viable cell number (determined as above) was used to calculate Loewe synergy scores using the Loewe additivity
model. P≤ 0.01 (**), P≤ 0.05 (*), ns (not signiﬁcant) as determined by unpaired or paired two-tailed t-test. f A375 cells were treated with increasing
concentrations of vemurafenib (Vem) with or without 1 μM AZD5991 for 48 h. Cell cycle proﬁle was determined by propidium iodide staining and ﬂow
cytometry. g, h A375 cells were treated with increasing concentrations of vemurafenib (Vem) (g) or selumetinib (Sel) (h) with or without 1 μM AZD5991
for 48 h. i The indicated tumour cell lines were treated with DMSO control (C), 1 μM vemurafenib (Vem), 1 μM selumetinib (Sel) and 0.3 μM SCH772984
(SCH) alone or in combination with 1 μM AZD5991, 1 μM AZD4320 and 20 μM Q-VD-OPh (QVD) for 48 h. j–o A375 (j, k), COLO205 (l, m) or SW620
(n, o) cells were treated with increasing concentrations of AZD5991 (j, l, n) or AZD4320 (k, m, o) with or without 1 μM selumetinib (Sel) for 48 h.
p, q A375 (p) and SK-MEL-30 (q) cells were treated with increasing concentrations of A-1155463 with or without 1 μM selumetinib (Sel) and 3 μM
venetoclax for 48 h. g–q Apoptosis was assessed by Annexin V positivity using ﬂow cytometry. Results (a–q) are the mean of at least three independent
experiments and error bars show SD
Fig. 3 BRAFi or MEKi combine with AZD5991 to inhibit melanoma cell survival and tumour growth. a A375 cells seeded at low density were treated with
DMSO control (C), 2 μM vemurafenib (Vem), 1 μM AZD5991 or the combination for 72 h. b A375 cells seeded at low density were treated with DMSO
control (C), 1 μM selumetinib (Sel), 1 μM AZD5991 or the combination for 72 h. c A375 cells seeded at low density were treated with DMSO control (C),
2 μM vemurafenib (Vem), 1 μMAZD4320 or the combination for 72 h. a–c Following treatment cells were washed and grown in inhibitor free medium for a
further four days. Colonies were then visualised by crystal violet staining and counted and then growth assessed following solubilisation. Results are mean
± SD of three or more independent experiments. P≤ 0.0001 (****), P≤ 0.05 (*) or ns (not signiﬁcant) as determined by one-way ANOVA and Sidak’s
multiple comparisons test. d, e Female nude athymic mice were implanted subcutaneously with A375 cells and randomised 21 days later for dosing with
either vehicle-only (Control, n= 5), 25mg kg−1 selumetinib (Sel, n= 7) twice daily with an 8 h interval, 60mg kg−1 AZD5991 (n= 7) intravenously once
weekly, or the combination of 25 mg kg−1 selumetinib and 60mg kg−1 AZD5991 (Sel+AZD5991, n= 8) for a further 21 days. Tumour growth was
recorded twice weekly and results are mean ± SEM (d) or mean % change in tumour volume ± SEM (e). P≤ 0.0001 (****), P≤ 0.001 (***) or P≤ 0.05 (*),
as determined by two-way ANOVA and Holm-Sidak’s multiple comparisons test
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pathway was inhibited was observed in melanoma cell lines and
primary patient-derived melanoma cells.
BRAFi or MEKi combinations with AZD5991 were also
effective in BRAF-mutant PDX models (Fig. 4g–n and
Supplementary Fig. 9a–f). While the BRAFi vemurafenib induced
moderate initial regressions of BRAFV600E-mutant MEDI-MEL-
02 PDX tumours, combination with AZD5991 caused sustained
near-complete tumour regressions (Fig. 4g, h and Supplementary
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Fig. 9a). Similarly, AZD5991 substantially enhanced tumour
growth inhibition by trametinib (Fig. 4i, j and Supplementary
Fig. 9b). In another PDX model, BRAFV600E-mutant MEDI-
MEL-10, AZD5991 again enhanced the efﬁcacy of vemurafenib or
trametinib despite this model being refractory to these ERK1/2
pathway inhibitors as monotherapies (Fig. 4k–n). These PDX
models represented extremes of response to ERK1/2 pathway
inhibition; MEDI-MEL-02 tumour growth was halted by
vemurafenib or trametinib, whereas MEDI-MEL-10 tumours
were unresponsive (Fig. 4g–n). However, AZD5991 was able
to combine with BRAFi or MEKi to regress or inhibit
tumour growth and these combinations were well tolerated
(Supplementary Fig. 9g–j).
Altogether these results indicate that the melanoma bias
towards MCL1 provides a therapeutic opportunity for combina-
tion with multiple ERK1/2 pathway inhibitors, including the
clinically approved BRAFV600-mutant selective inhibitor vemur-
afenib and MEKi such as selumetinib or trametinib, thereby
promoting striking tumour cell apoptosis and enhancing tumour
growth inhibition in vivo.
BRAFi or MEKi prime melanoma for MCL1i-induced death.
To deﬁne the mechanisms underpinning synergy between ERK1/2
pathway inhibition and AZD5991 we assessed the kinetics of the
apoptotic response. Addition of AZD5991 to A375 cells pre-treated
with vemurafenib or selumetinib for 24 h resulted in a time-
dependent increase in annexin V-positive cells (Fig. 5a and Sup-
plementary Fig. 10a). This rapid induction of apoptosis was even
more apparent at the level of DNA cleavage, suggesting that DNA
fragmentation preceded phosphatidylserine membrane leaﬂet ﬂip-
ping (Fig. 5b). Similar rapid apoptosis also occurred following
addition of AZD5991 to WM266-4 or SK-MEL-30 cells pre-treated
with vemurafenib or selumetinib, respectively (Fig. 5c, d).
Accumulation of annexin V-positive cells was preceded by
caspase activation. Selumetinib pre-treatment of A375 cells for
24 h, or treatment with AZD5991 alone, had little effect on
caspase-3/-7 activity. However, in cells pre-treated with selume-
tinib, caspase-3/-7 activity increased ~5-fold after 2 h AZD5991
treatment, reaching a plateau (~20-fold increase) after 8 h
(Fig. 5e). Caspase activation was preceded by activation of the
key apoptotic effector BAX, assessed using the 6A7 antibody that
recognises an amino-terminal epitope exposed only when BAX is
activated (Fig. 5f). In A375 cells pre-treated with selumetinib for
24 h, AZD5991 caused activation of BAX within 15 min that
reached a plateau after 2–4 h (Fig. 5f). Thus, ERK1/2 pathway
inhibitors primed ERK1/2-dependent tumour cells to undergo an
immediate activation of the canonical cell intrinsic apoptotic
pathway following MCL1 inhibition.
To examine whether apoptosis required BAK, BAX or both, we
utilised isogenic HCT116 cells lacking either BAK, BAX or both
(BAK BAX DKO)38 (Fig. 5g). Although HCT116 is a CRC cell
line, a combination effect with AZD5991 is still observed, albeit
more modest than that observed with A375 or SK-MEL-30. BAK
knock-out (KO) cells showed no apoptotic defect in response to
either selumetinib or combination with AZD5991 (Fig. 5h),
whereas cells lacking BAX exhibited a 60% reduction in apoptosis.
Finally, BAK BAX double knock-out (DKO) cells were completely
resistant to the modest pro-apoptotic effects of selumetinib or the
more striking response to combined selumetinib+AZD5991
(Fig. 5h). So while BAX was the more important effector in
HCT116, there was some redundancy with BAK. Regardless, the
combination killed cells in a BAK/BAX-dependent manner,
conﬁrming the anticipated on-target mechanism of this drug
combination. In addition, this combination did not increase the
fraction of necrotic cells, only apoptotic cells, and BAX knock-out
also prevented the accumulation of cells with sub-G1 DNA
(Fig. 5i and Supplementary Fig. 10b).
BRAFi or MEKi plus MCLi drives BIM- and BMF-dependent
apoptosis. We next examined how ERK1/2 pathway inhibition
and/or AZD5991 inﬂuenced expression of the BCL2 protein
family, the upstream regulators of BAK and BAX. Treatment of
A375 cells with vemurafenib (Fig. 6a) or selumetinib (Supple-
mentary Fig. 11a) increased expression of the pro-apoptotic BH3-
only proteins BIM and BMF in a concentration-dependent
manner as expected11. Inhibition of ERK1/2 also abolished
expression of NOXA, consistent with observations that NOXA
mRNA expression is promoted by ERK1/2 signalling39,40. Similar
results were observed in SK-MEL-30 cells with the MEKi selu-
metinib (Fig. 6b) and these cells also exhibited PUMA induction.
BRAFi or MEKi had more modest effects on other pro-apoptotic
and pro-survival BCL2 proteins (Fig. 6a, b and Supplementary
Fig. 11a). In both cell lines, 1 μM AZD5991 increased the abun-
dance of its target, MCL1, and caused loss of NOXA expression
(Fig. 6a, b). The increase in MCL1 expression likely reﬂects its
stabilisation because MULE, an E3 ubiquitin ligase for MCL1,
binds to MCL1 via a BH3 domain41 and so will be displaced by
AZD5991; thus, increases in MCL1 expression serve as a good
marker for MCL1 engagement by AZD5991. The reduction in
NOXA may also reﬂect its displacement from MCL1; certainly
some BH3-only proteins are intrinsically disordered and undergo
proteasome-dependent turnover when displaced from their
binding partners42,43. Combination of vemurafenib (Fig. 6c) or
selumetinib (Supplementary Fig. 11b) with increasing con-
centrations of AZD5991 promoted PARP cleavage indicative of
caspase-3 activation, and also reduced expression of BIM and
BMF slightly compared to ERK1/2 pathway inhibitor alone. In
A375 and SK-MEL-30 cells, MCL1 expression increased with
AZD5991 concentrations as low as 10 nM (Fig. 6c, d and Sup-
plementary Fig. 11b).
These results suggested that BIM and/or BMF might be
responsible for initiating apoptosis in response to combined
Fig. 4 BRAFi or MEKi combine with AZD5991 to inhibit growth of patient-derived xenografts. a, b MEDI-MEL-10 (a) and MEDI-MEL-07 (b) PDX cell lines
were treated with increasing concentrations of trametinib (Tra) with or without 1 μM AZD5991 for 72 h. c, d MEDI-MEL-10 (c) or MEDI-MEL-07 (d) cells
were treated with increasing concentrations of AZD5991 with or without 0.3 μM trametinib (Tra) for 72 h. e MEDI-MEL-10 cells were treated with
increasing concentrations of AZD4320 with or without 0.3 μM trametinib (Tra) for 72 h. fMEDI-MEL-10 cells were treated with increasing concentrations
of A-1155463 with or without 0.3 μM trametinib (Tra) and 3 μM venetoclax for 72 h. a–f Apoptosis was assessed by Annexin V positivity using ﬂow
cytometry. Results are mean ± SD of three or more independent experiments. g–n NOD SCID mice were implanted subcutaneously with MEDI-MEL-02
(g–j) or MEDI-MEL-10 (k–n) tumour pieces. Upon reaching 0.15–0.2 cm3 mice were randomised by tumour volume and body mass for dosing (n= 10 per
group for MEDI-MEL-02, n= 9 per group for MEDI-MEL-10) with vehicle-only (Control), 20mg kg−1 vemurafenib (Vem) twice daily with an 8 h interval,
1 mg kg−1 trametinib (Tra) daily, and/or 60mg kg−1 AZD5991 three times per week, as indicated. Mice were dosed on these schedules throughout the
duration of the experiment, except in m and n for which dosing ceased after day 32. Tumour growth was recorded twice weekly and results are mean ±
SEM (g, i, k, m) or mean % change in tumour volume ± SEM (h, j, l, n). P≤ 0.0001 (****), P≤ 0.001 (***), P≤ 0.01 (**) or P≤ 0.05 (*), as determined by
two-way ANOVA and Holm-Sidak’s multiple comparisons test
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inhibition of MCL1 and ERK1/2 signalling so we used CRISPR/
Cas9 gene editing to generate BIM KO, BMF KO or double
knock-out (BIM BMF DKO) A375 cells (Fig. 6e). We selected
three independent clones for each genotype and also three wild-
type clones that had been through CRISPR/Cas9 editing with
guides for BIM, BMF or both but were negative clones, retaining
normal expression of the targeted proteins and serving as controls
for off-target effects. These clones were compared with parental
A375 cells (Fig. 6f). We found that the striking cell death induced
by selumetinib+AZD5991 was inhibited ~50% by knock-out of
BIM or BMF whereas BIM BMF DKO cells exhibited a 65%
reduction in cell death (Fig. 6f). Thus, BIM and BMF make
signiﬁcant contributions to cell death arising from selumetinib+
AZD5991, likely acting through a shared mechanism. The
remaining cell death response might reﬂect contributions from
PUMA and BAD, which exhibited modest increases in abundance
in response to vemurafenib (Fig. 6a) or selumetinib (Supplemen-
tary Fig. 11a). A very similar dependency upon BIM and BMF
was observed in SK-MEL-30 cells. Knock-out of BIM and BMF
(BIM BMF DKO) (Fig. 6g) inhibited apoptosis induced by
selumetinib+AZD5991 by 60–70% compared to parental cells
and wild-type clones that, as above, retained normal BIM and
Fig. 5 ERK1/2 pathway inhibitors prime melanoma cells for rapid apoptosis following MCL1i. a, b A375 cells were treated with DMSO vehicle-only
(Control) or 2 μM vemurafenib (Vem) for 24 h as indicated. One micromolar AZD5991 was then added for the indicated times. Apoptosis was assessed by
Annexin V ﬂow cytometry (a), or cells ﬁxed, stained with propidium iodide and cell cycle proﬁle determined by ﬂow cytometry (b). c, dWM266-4 (c) and
SK-MEL-30 (d) cells were treated with DMSO vehicle-only (Control), 1 μM vemurafenib (Vem) or 1 μM selumetinib (Sel) for 24 h as indicated. One
micromolar AZD5991 was then added for the indicated times and apoptosis assessed by Annexin V staining and ﬂow cytometry. e A375 cells were treated
with DMSO vehicle-only (Control) or 1 μM selumetinib (Sel) for 24 h. One micromolar AZD5991 was then added for the indicated times and relative
caspase-3/-7 activity measured. f A375 cells were treated with DMSO vehicle-only (Control) or 1 μM selumetinib (Sel) for 24 h followed by combination
with 1 μM AZD5991 for the indicated times. BAX activation was determined using anti-BAX antibody clone 6A7, an N-terminal antibody speciﬁc for an
active conformation of BAX, and ﬂow cytometry. A representative ﬂow cytometer trace is shown (left) alongside pooled results (right). g HCT116, HCT116
BAK KO, HCT116 BAX KO and HCT116 BAK BAX DKO isogenic cell lines were lysed and western blotted with the indicated antibodies. h, i HCT116, HCT116
BAK KO, HCT116 BAX KO and HCT116 BAK BAX DKO isogenic cell lines were treated with DMSO control (C), 2 μM selumetinib (Sel), 1 μM AZD5991 or
2 μM selumetinib plus 1 μM AZD5991 (Sel+AZD5991) with or without 20 μM Q-VD-OPh (Sel+AZD5991+QVD) for 48 h, and cell death assessed by
Annexin V (h) or PI (i) staining and ﬂow cytometry. Results (a–f, h, i) are mean ± SD of three or more independent experiments. P≤ 0.0001 (****) and ns
(not signiﬁcant) as determined by two-way ANOVA and Tukey’s multiple comparisons test
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Fig. 6 Apoptosis induced by combined ERK1/2 pathway and MCL1 inhibition requires BIM and BMF. a A375 cells were treated with the indicated
concentrations of vemurafenib (Vem) with or without 1 μM AZD5991 for 24 h. b SK-MEL-30 cells were treated with the indicated concentrations of
selumetinib (Sel) with or without 1 μM AZD5991 for 24 h. c A375 cells were treated with the indicated concentrations of AZD5991 with or without 1 μM
vemurafenib (Vem) for 24 h. d SK-MEL-30 cells were treated with the indicated concentrations of AZD5991 with or without 1 μM selumetinib (Sel) for 24 h.
a–d Whole-cell lysates were western blotted with the indicated antibodies. e, f A375 cells and three independent clonally derived WT, BIM KO, BMF KO
and BIM BMF DKO A375 CRISPR clones were treated with 1 μM selumetinib (Sel) as indicated for 24 h and BIM and BMF expression assessed by western
blotting (e) or treated with DMSO-only control (C), 1 μM selumetinib (Sel), 1 μM AZD5991 or 1 μM selumetinib plus 1 μM AZD5991 (Sel+AZD5991) as
indicated for 48 h and apoptosis assessed by Annexin V staining and ﬂow cytometry (f). Results (f) show mean ± SD of three independent experiments.
P≤ 0.0001 (****), P≤ 0.01 (**) and ns (not signiﬁcant) as determined by two-way ANOVA and Tukey’s multiple comparisons test. g, h SK-MEL-30 cells
and three independent clonally derived WT and BIM BMF DKO SK-MEL-30 CRISPR clones were treated with 1 μM selumetinib (Sel) as indicated for 24 h
and BIM and BMF expression assessed by western blotting (g) or treated with DMSO-only control (C), 1 μM selumetinb (Sel), 1 μM AZD5991 or 1 μM
selumetinib plus 1 μM AZD5991 (Sel+AZD5991) as indicated for 48 h and apoptosis assessed by Annexin V staining and ﬂow cytometry (h). Results
(h) show mean ± SD of three independent experiments. P≤ 0.0001 (****) as determined by two-way ANOVA and Tukey’s multiple comparisons test
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BMF expression and induction following the CRISPR/Cas9
process (Fig. 6g, h).
Binding of AZD5991 to MCL1 should displace BH3-only
proteins such as BIM and BMF from MCL1, allowing them
to inhibit other pro-survival proteins to drive apoptosis. To
test this we treated A375 cells with vemurafenib, AZD5991 or
the combination and then immunoprecipitated (IP) either
MCL1 or BCL-XL before blotting for the presence of BIM and
BMF (Fig. 7a). Vemurafenib increased expression of BIM
and BMF and while these bound to both MCL1 and BCL-XL,
far more bound to MCL1 than to BCL-XL (Fig. 7a), consistent
with the high MCL1:BCL-XL ratio (~8) in these cells (Fig. 1 and
Supplementary Fig. 2). AZD5991 increased MCL1 abundance,
as seen in all experiments, but did not affect BIM or BMF
expression. Combination with AZD5991 slightly reduced the
vemurafenib-driven increase in BIM and BMF abundance.
Most strikingly, vemurafenib+ AZD5991 promoted a loss of
BIM and BMF from MCL1 and their binding to BCL-XL
(Fig. 7a); given the decrease in total BIM and BMF this is likely
an underestimate of the redistribution of these proteins to BCL-
XL. Very similar results were observed when selumetinib and
AZD5991 were combined in A375 and SK-MEL-30 cells
(Supplementary Fig. 11c, d). Thus, AZD5991 acted on-target
to drive redistribution of BIM and BMF from MCL1 on to other
pro-survival BCL2 proteins, including BCL-XL, which are not
themselves targets of AZD5991. Notably, since BIM may
activate BAX directly as well as indirectly through inhibition
of pro-survival proteins44,45, combination of vemurafenib or
selumetinib with AZD5991 also increased the amount of free
unbound BIM (Fig. 7a and Supplementary Fig. 11c, d).
In contrast to MCL1 inhibition by AZD5991, we observed
minimal redistribution of BIM and BMF when BCL-XL was
inhibited by A-1155463 in conjunction with ERK1/2 signalling in
A375 cells, consistent with the high MCL1:BCL-XL ratio in these
cells (~8) (Figs. 1 and 7b and Supplementary Fig. 2). The BCL-XL
inhibitor A-1155463 displaced BIM and BMF from BCL-XL, but
caused little accumulation on to MCL1 or increase in the fraction
of free BIM and BMF not bound to BCL-XL (Fig. 7b). This was
not due to loss of BIM and BMF expression in the presence of the
combination; indeed, BIM and BMF expression was only reduced
in combinations that caused strong PARP cleavage and cell death
(Fig. 7a, b and Supplementary Fig. 11c, d). Thus, this is consistent
with a more minor role for BCL-XL in these melanoma cells.
Taken together these results indicate AZD5991 acts on-target
in melanoma to inhibit MCL1 and strongly synergises with
ERK1/2 pathway inhibitors that drive BIM and BMF expression
Fig. 7 Combined BRAFi and MCL1i redistributes BIM and BMF to other pro-survival proteins. a A375 cells were treated with DMSO vehicle-only (C and
5991) or 2 μM vemurafenib (Vem and Vem+ 5991) for 24 h followed by DMSO-only (C and Vem) or 1 μM AZD5991 (5991 and Vem+ 5991) for a further
4 h. Lysates (input) were subjected to immunoprecipitation with antibodies to BCL-XL or MCL1. Input lysates, immunoprecipitates (IP) and supernatant
unbound fractions (UNB) were then western blotted using the indicated antibodies. b A375 cells were treated with DMSO vehicle-only (C and 1155) or
2 μM vemurafenib (Vem and Vem+ 1155) for 24 h followed by DMSO-only (C and Vem) or 0.1 μM A-1155463 (1155 and Vem+ 1155) for a further 4 h.
Lysates (input) were subjected to immunoprecipitation with antibodies to BCL-XL or MCL1. Input lysates, immunoprecipitates (IP) and supernatant
unbound fractions (UNB) were then western blotted using the indicated antibodies
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to promote BAK/BAX-dependent apoptosis; this arises through
redistribution of BIM and BMF from MCL1 on to other pro-
survival proteins and an increase in free BIM, which may directly
activate BAX.
ERKi plus MCL1i overcomes BRAFi and/or MEKi resistance.
Our results indicated that AZD5991 would combine very well
with BRAFi and/or MEKi as a primary, up-front drug combi-
nation but we also assessed activity in models of acquired
resistance. BRAFi+MEKi is now the standard for con-
sistency care for melanoma with BRAFV600E/K 6,7; however,
acquired resistance still emerges, typically through reactivation
of ERK1/2, and this is fuelling the development of ERK1/2
inhibitors46. We generated A375 sub-lines with acquired
resistance to PLX4720 (a vemurafenib analogue) (Supplemen-
tary Fig. 12a), selumetinib (Supplementary Fig. 12b) or the
combination of PLX4720+ selumetinib at ﬁve- or 10-times the
IC50 concentrations (Fig. 8a and Supplementary Fig. 12c). Next-
generation sequencing revealed that PLX4720/selumetinib-
resistant A375 sub-lines exhibited NRASQ61R and MEK1Q56P
mutations (Supplementary Fig. 12d–g). Whereas BRAF copy
number and expression were unchanged in both PLX4720/
selumetinib-resistant A375 sub-lines, selumetinib-resistant
A375 cells harboured BRAF ampliﬁcation and upregulation of
BRAF expression, whereas PLX4720-resistant cells expressed
a putative splice variant of BRAFV600E (Supplementary
Fig. 13a–f); these are well deﬁned mechanisms of resistance to
MEKi or BRAFi, respectively5,47–49. In each case these
mechanisms reinstated ERK1/2 signalling in the presence of the
respective inhibitor (Supplementary Fig. 13e); however, ERK1/
2 signalling in these resistant sub-lines remained sensitive to
the selective ERK1/2 inhibitor SCH772984 (Supplementary
Fig. 13f). This ERK1/2 inhibitor again combined well with
AZD5991 to kill parental A375 cells (Fig. 8a and Supplementary
Fig. 12a–c). Signiﬁcantly, this cell death response was fully
maintained in PLX4720/selumetinib-resistant A375 cells
(Fig. 8a and Supplementary Fig. 12c), as well as the cell lines
resistant to PLX4720 (Supplementary Fig. 12a) or selumetinib
(Supplementary Fig. 12b) monotherapy.
To see if this activity of ERKi+MCL1i was maintained in vivo
we employed tumour xenografts using the PLX4720/selumetinib-
resistant A375 cells. For these studies we used the ERKi
AZ619750, due to the poor pharmacokinetic properties of
SCH772984. AZD5991 had no activity as monotherapy against
the PLX4720/selumetinib-resistant A375 cells (Fig. 8b), as was
seen in cell culture studies (Fig. 8a). AZ6197 caused signiﬁcant
inhibition of tumour growth, consistent with ERKi being able to
overcome acquired resistance to BRAFi+MEKi, but this effect
was transient. AZD5991 combined with AZ6197 to cause a more
profound and durable tumour growth inhibition (Fig. 8b). Again
this was striking given that AZD5991 was dosed once weekly, a
schedule that likely results in MCL1 engagement for just a few
hours per week. AZ6197 alone, or in combination with AZD5991,
was well tolerated (Supplementary Fig. 13g). These results
indicate that, as well as use in an up-front combination with
BRAFi and/or MEKi, AZD5991 can be used in combination with
an ERKi to overcome acquired resistance to BRAFi and/or MEKi
driven by a variety of mutations in ERK1/2 pathway components.
Despite the efﬁcacy of AZD5991 in these combination studies
experience shows that acquired resistance is inevitable. To model
this we generated A375 cells adapted to grow in vemurafenib
(Vem-R), AZD5991 (5991-R) or the combination (Vem/5991-R)
in three independent experiments. Cumulative population
doublings showed that AZD5991 had no effect on A375 cell
proliferation (Fig. 8c). Vemurafenib caused a complete cessation
of A375 proliferation for ~2.5-weeks before resistant cells started
to emerge and proliferate whereas combination with AZD5991
doubled the time to resistance, with Vem/5991-R-resistant cells
emerging after 5–10 weeks (Fig. 8c, d). Vem-R cells exhibited a
previously described BRAF splice variant that likely allowed them
to maintain p-MEK1/2 and p-ERK1/2 in the presence of
vemurafenib49 (Fig. 8e). Interestingly 5991-R cells exhibited
higher levels of MCL1, though this was reduced slightly following
withdrawal of AZD5991, suggesting that this might simply
represent AZD5991 binding and stabilisation of MCL1 as
described above. Vem/5991-R A375 cells did not express any
apparent BRAF splice variant, suggesting that this drug
combination selected for reinstatement of ERK1/2 signalling
through another mechanism (Fig. 8e). Signiﬁcantly, all resistant
cells, whether to monotherapy or combination, retained p-MEK1/
2 and p-ERK1/2, and all Vem-R, 5991-R and Vem/5991-R
remained sensitive to ERKi SCH772984 (Fig. 8d and Supplemen-
tary Fig. 14a, b). Thus, adaptation or acquired resistance to
vemurafenib, AZD5991 or vemurafenib+AZD5991 could be
overcome by combination with an ERK1/2 inhibitor.
Combination with AZD5991 also doubled the time taken for
vemurafenib resistance to emerge in WM266-4 cells (Fig. 8f), and
increased the time to selumetinib resistance in SK-MEL-30 cells
by ~50% (Fig. 8g and Supplementary Fig. 14c). As with A375
cells, SK-MEL-30 cells acquired resistance to selumetinib
monotherapy and selumetinib combination with AZD5991 by
reinstating p-MEK1/2 and p-ERK1/2 in the presence of inhibitor
(Supplementary Fig. 14d), and similarly acquired resistance to
selumetinib or selumetinib+AZD5991 could be overcome using
the ERK1/2 inhibitor SCH772984 (Supplementary Fig. 14c).
Thus, AZD5991 can delay acquired resistance to BRAFi or MEKi
in BRAF-mutant or NRAS-mutant melanoma cells.
Discussion
While the BRAFi+MEKi combination has transformed the
treatment of BRAFV600E/K-mutant melanoma, clinical responses
are transient due to the emergence of resistance. This reﬂects the
fact that even strong ERK1/2 inhibition exerts a predominantly
cytostatic effect despite causing a substantial increase in pro-
apoptotic BIM, BMF and in some cases PUMA. This is also true
in other tumour lineages, such as CRC; however, whereas
increased BIM and BMF primed CRC cells to undergo substantial
apoptosis following treatment with the BCL2/BCL-w/BCL-XL
inhibitor navitoclax/ABT-26311,25,26, this combination was
notably less effective in melanoma11,27,28. This prompted us to
examine the expression of pro-survival proteins. Interrogation of
CCLE and TCGA data sets indicated that the medianMCL1:BCL-
XL mRNA ratio was two- to fourfold higher in melanoma than in
CRC, NSCLC and pancreatic cancer lineages. This was conﬁrmed
by western blotting and absolute protein quantiﬁcation, which
revealed that low BCL-XL expression biased the pro-survival
protein pool strongly towards MCL1 in melanoma.
Our results reveal that this lineage-selective MCL1 bias predicts
the response to the MCL1i AZD5991, but only in combination
with agents that inhibit ERK1/2 signalling to drive BIM and BMF
expression. MCL1i monotherapy, even at higher concentrations,
induced little apoptosis of melanoma (or CRC) tumour cells
in vitro and did not inhibit cell division during long-term culture,
while in vivo AZD5991 alone did not inhibit the growth of
melanoma xenografts. Therefore, melanoma tumour cells are
not dependent on MCL1 for survival per se; rather they are
dependent on MCL1, to a far greater extent than the other pro-
survivals, when the ERK1/2 pathway is inhibited. Presumably,
without induction of BIM and/or BMF the basal level of other
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pro-survival proteins represents a sufﬁcient barrier to prevent
apoptosis when MCL1 is inhibited.
These results suggest that melanoma represents a unique
opportunity as a disease in which two broad therapeutic windows
(ERK1/2 addiction and MCL1 addiction) are inter-dependent,
with MCL1 addiction only manifest when ERK1/2 signalling
is inhibited. This synthetic lethality will be best leveraged
using BRAF inhibitors such as vemurafenib, which speciﬁcally
inhibit ERK1/2 signalling in BRAFV600-mutant tumour cells,
but may also transform the potential of MEKi and ERKi in
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ERK1/2-addicted melanoma tumour cells. This is reﬂected in
striking synergistic cell death in vitro and tumour regression or
enhanced growth inhibition in vivo when BRAFi or MEKi and
AZD5991 are combined as an up-front combination.
Mechanistic studies demonstrated that ERK1/2 inhibition
primes melanoma cells to undergo apoptosis following sub-
sequent MCL1 inhibition. This apoptosis required increased
expression of BIM and BMF, which appear to play overlapping
roles; the remaining 20–25% cell death in BIM BMF DKOs may
reﬂect contributions from BAD and PUMA, both of which
increased in expression following ERK1/2 inhibition. Apoptosis
following addition of AZD5991 to primed cells was rapid, with
maximal BAX activation after 2–4 h, underscoring the extent to
which these cells are addicted to MCL1 to restrain the BIM and
BMF induced by ERK1/2 inhibition. Consistent with this, when
MCL1 was inhibited we observed redistribution of BIM and BMF
from MCL1 on to BCL-XL and an increase in free unbound BIM
that may activate BAX directly44,45. NOXA exhibits highly
selective binding to MCL1 (and A1) vs. BCL2, BCL-w or BCL-
XL11,51,52, and consistent with previous reports was dramatically
lost when the ERK1/2 pathway was inhibited (Fig. 6). This loss of
NOXA presumably dampens the apoptotic response to ERK1/2
pathway inhibitor monotherapy but further primes MCL1 with
BIM and BMF. Release of this BIM and BMF upon inhibition of
MCL1 may therefore accentuate the synergistic effect of com-
bined ERK1/2 pathway and MCL1 inhibition.
Critically, AZD5991 was also active in melanoma cells with
acquired resistance to BRAFi+MEKi, the current standard of
care for BRAFV600E/K melanoma. These cells acquired resistance
through the emergence of NRAS and MEK1 mutations to
reinstate ERK1/2 signalling and remained sensitive to ERKi.
Signiﬁcantly ERKi still combined with MCL1i to kill BRAFi+
MEKi-resistant tumour cells in vitro and inhibit their growth as
tumour xenografts in vivo.
Finally, AZD4320 (a BCL2/BCL-w/BCL-XL inhibitor) syner-
gised with ERK1/2 pathway inhibitors to induce apoptosis more
strongly than AZD5991 in CRC, a disease with common KRAS or
BRAF mutations that is as yet poorly served by ERK1/2 pathway
inhibition. The reciprocal was true in melanoma, where combi-
nation with AZD5991 generally resulted in greater synergy and
apoptosis than combination with AZD4320. Despite high
expression of BCL2 in melanoma compared to other lineages, the
response to AZD4320 was not replicated by selective BCL2
inhibition with venetoclax, but rather was recapitulated using the
selective BCL-XL inhibitor A-1155463. Thus, although either
BCL2/BCL-w/BCL-XL or MCL1 inhibitors can synergise to some
extent with ERK1/2 pathway inhibitors in a broad range of
lineages11,26,27,53,54, the ability to target individual pro-survival
proteins as BH3-mimetic-speciﬁcity continues to be reﬁned will
allow antagonism of only those critical pro-survival proteins that
limit apoptotic responses to ERK1/2 pathway inhibitors in a
particular lineage, thereby improving the therapeutic window of
these combinations. Whereas BRAFi and MEKi are approved for
use in melanoma, current clinical studies are investigating
how best to combine BRAFi and/or MEKi with other targeted
agents in CRC and other solid tumours such as NSCLC and
pancreatic55,56. Our results suggest that in CRC ERK1/2 inhibi-
tion may combine better with antagonists of BCL-XL than MCL1
due to their relative expression, further underlining the potential
for tumour lineage-selective differences that will drive BH3-
mimetic combination choices; as we show here, the ratio of pro-
survival proteins will be informative in this choice, and represent
a potential clinical biomarker.
In summary, our results demonstrate that targeting melano-
ma’s MCL1 bias unleashes the potential of BRAF and ERK1/2
pathway inhibitors by transforming cytostatic responses into
striking apoptotic cell death. This approach results in superior
tumour regressions or growth inhibition and could afford a broad
therapeutic window in patients. Since BRAFi and MEKi are
already approved for treatment of BRAFV600E/K-positive mela-
noma, combination with MCL1i may provide an opportunity to
promptly improve patient outcomes.
Methods
Reagents and resources. A full list of reagents and resources used in this study is
provided in Supplementary Table 3. Further information and requests for resources
and reagents should be directed to Simon Cook (simon.cook@babraham.ac.uk).
Cell lines and culture. Human colorectal cancer (CRC) cell lines Caco-2,
COLO205, DLD-1, HT29, LS174T, LS411N, NCI-H747, SK-CO-1, SW48, SW480,
SW620, SW1116 and SW1417 were from ATCC (LGC Standards, Middlesex, UK).
HCA7, HCT8 and SW837 cells were from ECACC (Culture Collections, Public
Health England, Salisbury, UK). CO115 cells were provided by Dr. Richard
Hamelin (INSERM, Paris, France) and LoVo by Professor Kevin Ryan (The
Beatson Institute for Cancer Research, Glasgow, UK). HCT116 cells and isogenic
derivatives lacking BAK and/or BAX were provided by Bert Vogelstein and Richard
Youle (NIH, Bethesda, Maryland, USA).
Human melanoma cell lines A2058, CHL-1, HMCB, MeWo, PMWK, RPMI-
7951, SK-MEL-2, SK-MEL-5, SK-MEL-28 and SK-MEL-31 were from ATCC. SK-
MEL-30 cells were from DSMZ (Leibniz Institute DSMZ-German Collection of
Microorganisms and Cell Cultures, Braunschweig, Germany). WM266-4 and
WM852 cells were from ESTDAB (European Searchable Tumour Cell and Data
Bank, Centre for Medical Research (ZMF), Tübingen, Germany). A375 cells were
provided by Richard Marais (Cancer Research UK Manchester Institute,
Manchester, UK). MEL-JUSO cells were provided by Professor Judith Johnson
Fig. 8 AZD5991 can delay and overcome acquired resistance to BRAFi and/or MEKi. a A375 and PLX4720/selumetinib-resistant A375 (A375 PLX/Sel-R2)
cells were washed and treated with 0.3 μM SCH772984 (SCH), 1 μM AZD5991 (5991) or the combination (SCH+ 5991) for 48 h, either in the presence
(PLX+ Sel) or the absence of 0.66 μM PLX4720 and 0.5 μM selumetinib, their normal growth medium. Cell cycle proﬁle was determined by propidium
iodide staining and ﬂow cytometry. Results show mean ± SD of four independent experiments. b Female athymic nude mice were injected subcutaneously
with A375 PLX/Sel-R2 cells. Once tumours reached an average of 0.2 cm3, mice were randomised in to treatment groups and dosed with vehicle-only
(Control, n= 10), 50mg kg−1 AZ13776197 (AZ6197, n= 10) orally once daily, 60mg kg−1 AZD5991 (AZD5991, n= 10) once weekly intravenously, or the
combination of 50mg kg−1 AZ6197 and 60mg kg−1 AZD5991 (AZ6197+AZD5991, n= 10). Tumour volume growth results are geometric mean ± SEM.
P≤ 0.01 (**) as determined by two-way ANOVA and Holm-Sidak’s multiple comparisons test. c A375 cells were cultured in the presence of DMSO-only
(Control), 2 μM vemurafenib (Vem), 1 μM AZD5991 or the combination (Vem+AZD5991) and the number of cumulative doublings recorded. Three
independent experiments are shown. d A375, vemurafenib-resistant A375 (Vem-R1) cells, AZD5991-resistant A375 (5991-R1) cells and vemurafenib/
AZD5991-resistant A375 (Vem/5991-R1) cells were treated with 2 μM vemurafenib (Vem), 1 μM AZD5991 (5991) with or without 1 μM SCH772984
(SCH) as indicated for 48 h. Cell cycle proﬁle was determined by propidium iodide staining and ﬂow cytometry. Results show mean ± SD of three
independent experiments. e A375, Vem-R1, 5991-R1 and Vem/5991-R1 were washed and treated with 2 μM vemurafenib (Vem) and/or 1 μM AZD5991
(5991) as indicated for 24 h. Whole-cell lysates were western blotted with the indicated antibodies. f WM266-4 cells were cultured in the presence of
DMSO-only (Control), 1 μM vemurafenib, 1 μM AZD5991 or Vem+AZD5991 and the number of cumulative doublings recorded. g SK-MEL-30 cells were
cultured in the presence of DMSO-only (Control), 1 μM selumetinib (Sel), 1 μM AZD5991 or Sel+AZD5991 for 16 weeks and the number of cumulative
doublings recorded
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(Institute of Immunology, University of Munich, Munich, Germany). MEDI-MEL-
07 and MEDI-MEL-10 primary patient-derived human melanoma cells were
provided by AstraZeneca (Gaithersburg, Maryland, USA).
Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520,
NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-
H2122 and NCI-H2286 were from ATCC. HARA cells were from JCRB (Japanese
Collection of Research Bioresources Cell Bank, National Institutes of Biomedical
Innovation, NIBIO, Osaka, Japan) and HCC15 cells were from DSMZ. Human
pancreatic adenocarcinoma cell lines AsPC-1, BxPC3, Capan-1, CFPAC-1, HPAC,
HPAF-II, Hs 700T, MIA PaCa-2, Panc 02.03, Panc 03.27, Panc 04.03, Panc 08.13,
Panc 10.05, PANC-1 and PSN1 were from ATCC. HuP-T4 and PSN1 cells were
from ECACC, and YAPC cells were from DSMZ.
Cells were grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (A375,
A549, A2058, CO115, DLD-1, HCA7, HCT116, Hs 700T, LoVo, MEDI-MEL-07,
MEDI-MEL-10, MIA PaCa-2, PANC-1), IMDM (CFPAC-1), Leibovitz’s L-15
(SW48, SW480, SW620, SW837, SW1116, SW1417), McCoy’s 5A (HT29), MEM
alpha (Calu-6, HMCB, HPAF-II, HuP-T4, LS174T, MeWo, PMWK, RPMI-7951,
SK-MEL-2, SK-MEL-5, SK-MEL-28, WM266-4, WM852) or RPMI 1640 (AsPC-1,
BxPC3, COLO205, HARA, HCC15, HCT8, LS411N, NCI-H520, NCI-H727, NCI-
H747, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-
H2122, NCI-H2286, PSN1, SK-MEL-30, YAPC) media supplemented with 10%
(v/v) fetal bovine serum, penicillin (100 UmL−1), streptomycin (100 mgmL−1)
and 2 mM glutamine. DMEM for MEDI-MEL-07 and MEDI-MEL-10 cells was
additionally supplemented with 0.1 mM non-essential amino acids and 25 mM
HEPES. Leibovitz’s L-15 media was additionally supplemented with 0.75 mgmL−1
sodium bicarbonate. Caco-2 cells were grown in MEM alpha, 20% (v/v) fetal
bovine serum, penicillin (100 UmL−1), streptomycin (100 mgmL−1) and 2 mM
glutamine. Capan-1 cells were grown in IMDM, 20% (v/v) fetal bovine serum,
penicillin (100 UmL−1), streptomycin (100 mgmL−1) and 2 mM glutamine.
HPAC cells were grown in 1:1 DMEM/Ham’s F12 medium mix, 0.002 mgmL−1
insulin (Sigma-Aldrich, Dorset, UK), 0.005 mgmL−1 transferrin (Sigma-Aldrich),
40 ng mL−1 hydrocortisone (Sigma-Aldrich), 10 ng mL−1 human recombinant
epidermal growth factor (Sigma-Aldrich) and 5% fetal bovine serum, penicillin
(100 UmL−1), streptomycin (100 mgmL−1) and 2 mM glutamine. Panc 02.03,
Panc 03.27, Panc 04.03, Panc 08.13 and Panc 10.05 cells were grown in RPMI 1640
medium, 15% (v/v) fetal bovine serum, 1 UmL−1 insulin, penicillin (100 UmL−1),
streptomycin (100 mgmL−1) and 2 mM glutamine. SK-MEL-31 cells were grown
in MEM alpha medium, 15% (v/v) fetal bovine serum, penicillin (100 UmL−1),
streptomycin (100 mgmL−1) and 2 mM glutamine. Cells were incubated in a
humidiﬁed incubator at 37 °C and 5% (v/v) CO2. All cell lines were authenticated
by short tandem repeat (STR) proﬁling and conﬁrmed negative for mycoplasma
prior to experiments commencing. Unless stated otherwise, the above reagents
were from Gibco, Thermo Fisher Scientiﬁc (Paisley, UK).
A375 cells with acquired resistance to PLX4720 (A375 PLX-R), selumetinib
(A375 Sel-R), or combined PLX4720 and selumetinib (A375 PLX/Sel-R1 and A375
PLX/Sel-R2) were provided by AstraZeneca. Cells were grown in RPMI 1640 media
supplemented with 10% (v/v) fetal bovine serum, penicillin (100 UmL−1),
streptomycin (100 mgmL−1), 2 mM glutamine and containing 0.66 μM PLX4720
(A375 PLX-R), 0.5 μM selumetinib (A375 Sel-R), 0.33 μM PLX4720 plus 0.25 μM
selumetinib (A375 PLX/Sel-R1) or 0.66 μM PLX4720 plus 0.5 μM selumetinib
(A375 PLX/Sel-R2).
Mice. All animal studies were conducted in accordance with the National Institute
of Health guidelines for animal research or with UK Home Ofﬁce regulations, UK
Animals (Scientiﬁc Procedures) Act of 1986 and approved by AstraZeneca’s
Institutional Animal Care and Use Committee (IACUC). Animals were kept in a
pathogen-free, AAALAC (Association for the Assessment and Accreditation of
Laboratory Animal Care) or UK Home Ofﬁce approved facilities on a 12 h light/
dark cycle. The ambient temperature was 21 ± 2 °C and the humidity was 55 ± 10%.
Mice were housed at 3–5 animals per cage with air exchange and cages were
changed weekly. Food and water were provided ad libitum.
Inhibitor compounds and cell culture treatments. AZD4320 (CAS: 1357576–48–7),
AZD5991 (CAS: 2143010–83–5), AZ6197 (compound 35)50 and selumetinib (CAS:
606143–52–6) were supplied by AstraZeneca. A-1155463 (CAS: 1235034–55–5) and
Q-VD-OPh (CAS: 1135695–98–5) were purchased from Adooq Bioscience (Irvine,
California, USA). PLX4720 (CAS: 918505–84–7), SCH772984 (CAS: 942183–80–4),
trametinib (CAS: 871700–17–3) and vemurafenib (CAS: 918504–65–1) were pur-
chased from Selleck Chemicals (Houston, Texas, USA). Venetoclax (CAS:
1257044–40–8) was purchased from MedChemExpress (New Jersey, USA). All
compounds were dissolved in dimethyl sulfoxide (DMSO) to a stock concentration
of 10mM.
For inhibitor compound treatments, cells were seeded into dishes or plates in
their normal growth medium (containing the relevant inhibitors for cells with
acquired resistance) and allowed to settle for 24 h. For experiments with resistant
cells, all treatment groups were washed with complete media only and then treated
with fresh media containing the indicated compounds or media containing vehicle-
only. Vehicle DMSO concentrations were normalised so that they were equivalent
for all treatments.
Generation of PLX4720- and/or selumetinib-resistant cells. To generate A375
cells with acquired resistance to either PLX4720 or selumetinib, cells at 50%
conﬂuence were treated with a GI50 concentration of PLX4720 (66 nM) or selu-
metinib (50 nM). Upon conﬂuence, the cells were split and the inhibitor con-
centration increased a 1 × GI50 step (i.e., from 66 to 132 nM PLX4720 and 50 to
100 nM selumetinib). This was continued for ~3–4 months until the cells grew
normally in 10 × GI50 PLX4720 (0.66 μM; A375 PLX-R) or selumetinib (0.5 μM;
A375 Sel-R).
To generate cell lines in parallel to those above with acquired resistance to both
PLX4720 and selumetinib, A375 cells at 50% conﬂuence were treated with a GI50
concentration of selumetinib (50 nM). Upon conﬂuence the cells were split and
additionally treated with 1 × GI50 PLX4720 (66 nM). Compound concentrations
were alternately increased a 1 × GI50 step following splitting until after 4 months
the cells grew normally in 5 × GI50 PLX4720/selumetinib (0.33 μM PLX4720 and
0.25 μM selumetinib; A375 PLX/Sel-R1). The same procedure was used to generate
an independent cell line in parallel with resistance to 10 × GI50 PLX4720/
selumetinib (0.66 μM PLX4720 and 0.5 μM selumetinib; A375 PLX/Sel-R2).
Generation of vemurafenib-, selumetinib- and/or AZD5991-resistant cells.
A375 or WM266-4 cells at 50% conﬂuence and growing in 175 cm3 tissue culture
ﬂasks were treated with 2 μM (A375) or 1 μM (WM266-4) vemurafenib and/or
1 μM AZD5991 as indicated in the Figure legends. SK-MEL-30 cells at 50% con-
ﬂuence and growing in 175 cm3 tissue culture ﬂasks were treated with 1 μM
selumetinib and/or 1 μM AZD5991 as indicated in the Figure legends.
Cells were then either split as required or media changed twice a week until all
cells grew at a stable rate for >4 weeks. Cumulative doublings tallies were calculated
by tracking splitting ratios and using the formula: number of doublings=
log2(splitting dilution factor).
CRISPR-mediated gene editing. Guide RNAs (gRNAs) to BCL2L11 (encoding
BIM) and BMF were designed using the Zhang laboratory gRNA designing tool
(http://crispr.mit.edu/) and cloned into a pSpCas9(BB)-2A-GFP genome editing
vector, which was a gift from Feng Zhang (Addgene plasmid #48138). The gRNA
sequences were BIM gRNA2 5′- caccGCAACCACTATCTCAGTGCAA-3′; 5′-
aaacTTGCACTGAGATAGTGGTTGC-3′ and BMF gRNA1 5′-caccGAAGA
GCTGAAGTCGGCTGA-3′; 5′-aacTCAGCCGACTTCAGCTCTTC-3′. A375 or
SK-MEL-30 cells were transfected with the BCL2L11 and/or BMF gRNA containing
Cas9 plasmids either individually or in combination using jetPRIME (Polyplus
Transfection, Illkirch, France). Transfection was monitored by green ﬂuorescent
protein (GFP) expression and single GFP-positive/4′,6-diamidino-2-phenylindole
(DAPI)-negative cells were sorted (Supplementary Data 1) in to 96-well plates
using a 100 μm nozzle on a BD FACSAria III cell sorter (BD Biosciences, Oxford,
UK). Clones of interest were identiﬁed by western blot screening for absence of
BIM and/or BMF as well as control clones (WT), which still fully expressed the
proteins despite transfection with the gRNA containing Cas9 plasmids. Uncropped
western blot images of these clones in Fig. 6e are shown in Supplementary Data 2.
To conﬁrm the presence or absence of BIM and BMF mutations genomic DNA
was extracted from A375 (control untransfected) and all WT, BIM and BMF single
and double KO clones. Cells were lysed with Tail Lysis Buffer (50 mM Tris pH 8.0,
5 mM EDTA, 0.25% SDS, 200 mM NaCl) and 200 μg mL−1 Proteinase K added to
the lysate prior to incubation at 55 °C overnight. An equivalent volume of phenol/
chloroform/isoamyl alcohol 25:24:1 (v/v) saturated with 10 mM Tris pH 8.0, 1 mM
EDTA (Sigma-Aldrich, Dorset, UK) was then added and tubes mixed by inversion.
After centrifugation, the DNA-containing aqueous phase was collected and
precipitated by adding 0.8 volumes of 100% isopropanol (Sigma-Aldrich, Dorset,
UK). The precipitated DNA was pelleted by centrifugation, washed with 70% (v/v)
ethanol and solubilised in nuclease-free water.
Genomic DNA ﬂanking the CRISPR guide-binding site was ampliﬁed by PCR
using OneTaq (NEB, Hitchin, UK) according to the manufacturer’s instructions
and using the following primers: BIM 5′-CTAACCCCGGGAAGTCAGAG-3′; 5′-
TTGACACATCCTCCATTCCC-3′ and BMF 5′-CGGCCTAGGTCAGAA
AACGTG-3′; 5′-GCAGGTGGAAGTCAAGGAATC-3′. The products generated
were then cloned into the TOPO-TA cloning vector (Thermo Fisher Scientiﬁc,
Loughborough, UK) following the manufacturer’s instructions. The resulting
constructs were used to transform chemically competent DH5α (NEB, Hitchin,
UK), and 4–5 of the resulting clones derived from DNA for each cell line were sent
for sequencing (Genewiz, Bishop’s Stortford, UK).
Xenograft studies. Compounds were formulated as follows. Selumetinib or tra-
metinib were dissolved in 0.5% (w/v) Methocel hydroxypropyl methylcellulose
(HPMC; Colorcon, Pennsylvania, USA)/0.1% (v/v) Polysorbate 80 (VWR, Penn-
sylvania, USA). Vemurafenib was dissolved in a 50/30/20 mixture of PEG-400
(MilliporeSigma, Massachusetts, USA), Koliphor-ELP (Sigma-Aldrich, St. Louis,
USA), and 60% Captisol (Cydex Pharamceuticals, Kansas, USA). Selumetinib,
trametinib and vemurafenib were protected from light and stored at room tem-
perature for up to 7 days. AZD5991 was dissolved in 30% (w/v) hydroxypropyl-β-
cyclodextrin (HPBCD; CTD Inc, Florida, USA)/1 M Meglumine (Sigma-Aldrich,
St. Louis, USA) and brought to pH 9.0. AZD5991 was prepared fresh each week.
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The ERK1/2 inhibitor AZ13776197 was formulated in a 10% (v/v) DMSO/36% (w/v)
HPBCD (Kleptose HPB-LB parenteral grade, Roquette, Corby, UK) vehicle.
Xenografts of A375 cells were performed in female nude athymic (Ncr-
Foxn1nu) mice (Taconic Biosciences, Rensselaer, New York, USA). Mice were
implanted subcutaneously with 5 × 106 A375 cells in a 50:50 mixture of phosphate
buffered saline (PBS):Matrigel (BD Biosciences, San Jose, California, USA).
Injection volume was 0.1 mL per mouse. Injections were performed on the right
ﬂank of the animal. Once palpable, tumours were measured twice weekly using
calipers and animal body masses recorded. Twenty-one days post-implantation
mice were randomised into treatment arms based on tumour size. The vehicle-only
control group contained ﬁve animals. All other arms contained seven to eight
animals. Selumetinib (25 mg kg−1) was dosed by oral gavage twice daily on an 8 h
interval. AZD5991 (60 mg kg−1) was injected intravenously once weekly. AZD5991
treatment was started 1 day after selumetinib and given 4 h after the morning dose
of the respective combination partner.
All tumour patient-derived xenograft (PDX) models used in this study came
from the internal AstraZeneca PDX library and had the appropriate patient
consent and Institutional Review Board (IRB) approval. MEDI-MEL-02 melanoma
(BRAFV600E mutant) was from a 50-year-old female and tumour tissue taken from
the right upper arm. The passage used in this study was P5. MEDI-MEL-10
melanoma (BRAFV600E mutant) was from a 72-year-old male and tumour tissue
taken from a lung metastasis. The passage used in this study was P6. Neither
patient had previously received BRAFi or MEKi. PDX tumours were initially
propagated in seed female NOD SCID (NOD.CB17-Prkdcscid/NCrHsd) mice
(Taconic Biosciences, Rensselaer, New York, USA), to generate sufﬁcient tumour
material to seed each efﬁcacy study. Once tumours reached 0.8–1.2 cm3 the mice
were humanely euthanised by CO2 asphyxiation. Tumours were isolated under
sterile conditions, cut into ~2–3 mm3 pieces and implanted subcutaneously into the
right ﬂank of individual 10–12-week-old female NOD SCID mice using a 10-gauge
trocar needle. Upon reaching an average size of ~0.15–2 cm3, mice were
randomised (based on tumour volume and body weight) using the multi-task
feature in Study Director software (Studylog Systems, California, USA) into the
various treatment groups. The method uses a randomised block design to cluster
mice into groups using both tumour volume and body mass. Mice were then dosed
with vemurafenib (20 mg kg−1 by oral gavage twice daily on an 8 h interval),
trametinib (1 mg kg−1 by oral gavage once daily) and/or AZD5991 (60 mg kg−1
intravenously three times per week on Monday, Wednesday and Friday). Tumour
volumes were measured twice weekly using calipers and animal body mass and
tumour condition also recorded twice weekly.
A375 Sel/PLX-R2 xenografts were performed in female athymic nude mice
(Hsd:Athymic Nude-Foxn1nu; Envigo, Huntingdon, UK). Mice were implanted
subcutaneously with 5 × 106 A375 Sel/PLX-R2 cells on the left ﬂank in a volume of
0.1 mL per mouse. On day 6 post-implant, mice were randomised into control and
treatment groups of 10 mice with an average tumour volume of ~0.2 cm3 and
dosing commenced the day after randomisation for a duration of 21 days. Mice
received 50 mg kg−1 AZ13776197 administered once daily by oral gavage starting
on day 1 post randomisation and 60 mg kg−1 AZD5991 was given once weekly
intravenously 2 h after administration of AZ13776197 starting from day 4 post
randomisation. Mice in control groups received a combination dose of both
vehicles used. Tumour volumes were measured twice weekly using calipers and
animal body mass and tumour condition also recorded twice weekly.
In all experiments tumour length (L) and width (W) were measured using
calipers and tumour volume calculated using the formula for the volume of a
prolate spheroid V= 4/3π(L/2)(W/2)².
High-throughput drug combination assays and synergy scores. Cells were
seeded in 384-well black wall imaging plates (ViewPlate-384, Perkin Elmer,
Buckinghamshire, UK) and allowed to settle for 24 h. Cells were then treated with
vemurafenib (top concentration 10 μM), trametinib (top concentration 0.3 μM),
selumetinib (top concentration 10 μM) or SCH772984 (top concentration 3 μM) in
combination with AZD5991 (top concentration 10 μM) or AZD4320 (top con-
centration 10 μM) in a half-log 8 × 8 concentration matrix. Drug dispensing was
performed using a cell::explorer HCS robot (Perkin Elmer, Buckinghamshire, UK).
Following 5 days treatment, cells were incubated with the DNA intercalating
ﬂuorescent dye Sytox Green (Thermo Fisher Scientiﬁc, Loughborough, UK) at 0.16
μM (diluted in TBS-EDTA buffer: 0.1 M Tris, 0.15 M NaCl, 5 mM EDTA, pH 7.0)
for 1 h and dead cells in each well imaged following ﬂuorescence stimulation at 488
nm using a Nikon Eclipse Ti-E microscope (Nikon, Nikon Instruments, Amster-
dam, Netherlands). Cells were then permeabilised by addition of 0.04% (w/v)
saponin/TBS-EDTA buffer for 4 h and total cells in each well imaged. Dead and
total cells in images were counted for each well using NIS-Elements Advanced
Research (Nikon, Nikon Instruments, Amsterdam, Netherlands) or Ilastik (http://
ilastik.org/). Cell numbers per well were also determined at the point of treatment
(day 0) using this methodology in parallel 384-well plates. The number of live cells
for both day 0 and day 5 was calculated by subtracting the dead read from the total
read. Data are shown using the NCI formulas [(L – L0)/(C – L0)] × 100 if L ≥ L0 and
[(L – L0)/L0] × 100 if L < L0, where L represents the number of live cells in the
presence of drug, L0 represents the number of live cells at time zero (day 0) and C
represents the control (DMSO-only vehicle) live cell number. This gives a 100%, 0,
−100% scale of live cell number, in which 100% is the control (DMSO-only
vehicle) live cell number, 0 is the day 0 live cell number and negative percentages
indicate cell death with −100% meaning no live cells were present. Three inde-
pendent experiments were performed for each drug combination and cell line.
Mean data are presented in heat maps generated using GraphPad Prism 7
(GraphPad Software, La Jolla, California, USA). Synergy scores were generated
using the Loewe additivity model and calculated in the combination extension of
Genedata Screener 12 (Genedata, Basel, Switzerland). Unless otherwise indicated,
reagents were from Sigma-Aldrich, Dorset, UK.
Preparation of cell lysates for sodium dodecyl sulphate–
polyacrylamidegel electrophoresis (SDS-PAGE) and western blotting. Culture
medium from cells growing on dishes was either removed or non-adherent cells/
cellular material recovered from the medium by centrifugation (400 × g at room
temperature (RT) for 3 min (min)). Cells were washed with PBS and then lysed for
5 min with ice-cold RIPA lysis buffer (20 mM Tris-HCl (pH 7.4), 137 mM NaCl, 1
mM EGTA, 1% (v/v) Triton X-100, 0.1% (w/v) SDS (Bio-Rad, Watford, UK), 1%
(w/v) sodium deoxycholate, 10% (v/v) glycerol, 1.5 mM MgCl2, 50 mM NaF, 1 mM
Na3VO4, 5 μg mL−1 aprotinin, 10 μg mL−1 leupeptin, 1 mM PMSF, 0.025 UmL−1
Benzonase). Lysates were detached and collected using a cell scraper and trans-
ferred to pre-chilled tubes. Protein concentration was determined by BCA protein
assay (Pierce BCA Protein Assay Kit, Thermo Fisher Scientiﬁc, Loughborough,
UK) and absorbance measured at 562 nm using a PHERAstar FS plate reader
(BMG Labtech, Aylesbury, UK). Samples were prepared for SDS-PAGE by boiling
for 5 min in 1 × Laemmli sample buffer (50 mM Tris-HCl (pH 6.8), 2% (w/v) SDS
(Bio-Rad, Watford, UK), 10% (v/v) glycerol, 1% (v/v) β-mercaptoethanol, 0.01%
(w/v) bromophenol blue). Unless otherwise indicated, reagents were from Sigma-
Aldrich, Dorset, UK.
Preparation of tumour tissue homogenates. Colorectal and melanoma PDX
tumour tissue was from the internal AstraZeneca PDX library. Snap frozen tumour
fragments were homogenised in ice-cold RIPA lysis buffer (20 mM Tris-HCl (pH
7.4), 137 mM NaCl, 1 mM EGTA, 1% (v/v) Triton X-100, 0.1% (w/v) SDS (Bio-
Rad, Watford, UK), 1% (w/v) sodium deoxycholate, 10% (v/v) glycerol, 1.5 mM
MgCl2, 50 mM NaF, 1 mM Na3VO4, 5 μg mL−1 aprotinin, 10 μg mL−1 leupeptin,
1 mM PMSF, 0.025 UmL−1 Benzonase) using gentleMACS M tubes and a gen-
tleMACS Dissociator on setting Protein_0.1.01 (Miltenyi Biotec, Surrey, UK).
Lysates were collected by centrifugation (400 × g, 4 °C, 1 min) and protein con-
centration determined by BCA protein assay (Pierce BCA Protein Assay Kit,
Thermo Fisher Scientiﬁc, Loughborough, UK) and absorbance measured at 562 nm
using a PHERAstar FS plate reader (BMG Labtech, Aylesbury, UK). Samples were
prepared for SDS-PAGE by boiling for 5 min in 1 × Laemmli sample buffer (50 mM
Tris-HCl (pH 6.8), 2% (w/v) SDS (Bio-Rad, Watford, UK), 10% (v/v) glycerol, 1%
(v/v) β-mercaptoethanol, 0.01% (w/v) bromophenol blue). Unless otherwise indi-
cated, reagents were from Sigma-Aldrich, Dorset, UK.
SDS-PAGE and western blotting. Lysates were separated by SDS-PAGE (Mighty
small II gel apparatus, Hoefer, Massachusetts, USA). Polyacrylamide gels consisted of
a resolving phase of 8–16% (w/v) acrylamide (37.5:1 acrylamide:bisacrylamide, 2.7%
crosslinker; Bio-Rad, Watford, UK), 0.375M Tris-HCl (pH 8.8), 0.2% (w/v) SDS
(Bio-Rad, Watford, UK), 0.1% (w/v) ammonium persulfate, 0.1% TEMED (Bio-Rad,
Watford, UK) and a stacking phase of 4.5% (w/v) acrylamide (37.5:1 acrylamide:
bisacrylamide, 2.7% crosslinker), 0.125M Tris-HCl (pH 6.8), 0.2% (w/v) SDS, 0.1%
ammonium persulfate, 0.125% TEMED. Gels were run using running buffer (0.2M
glycine, 25mM Tris, 0.1% (w/v) SDS) and a current of 15mA per gel for 3–4 h. Gels
were then blotted by wet transfer (Bio-Rad, Watford, UK) to methanol activated
PVDF (Immobilon-P Membrane, Merck Millipore, Watford, UK) using transfer
buffer (0.2M glycine, 25mM Tris, 20% (v/v) methanol) and a current of 300mA for
90min. Membranes were blocked in 5% milk/TBST (5% (w/v) non-fat powdered
milk (Marvel, Premier Foods, St Albans, UK), 10 mM Tris-HCl (pH 7.6), 150 mM
NaCl, 0.1% (v/v) Tween-20) for 1 h at room temperature. For quantiﬁcation of
total protein using REVERT and processing using the Odyssey system, membranes
were incubated for 5 min with REVERT solution and washed following the man-
ufacturer’s instructions (LI-COR, Cambridge, UK), and then blocked in 5% milk/
PBS for 1 h. Membranes were incubated with primary antibodies against ARAF,
BAD, BCL-XL, BID, BIM, ERK1/2, MCL1, MEK1/2, PARP, phospho-ERK1/2
(T185 Y187/T202 Y204), phospho-MEK1/2 (S218 S222/S222 S226), phospho-RSK
(T359), PUMA, RSK (Cell Signalling Technology, NEB, Hitchin, UK), BAK, BAX,
BCL2, BRAF, CRAF, MCL1, NRAS (Santa Cruz Biotechnology, Dallas, USA), BAX
(BD Biosciences, Oxford, UK), BIM, NOXA (Merck Millipore, Watford, UK), BMF
(Enzo Life Sciences, Exeter, UK), GAPDH (Abcam, Cambridge, UK), KRAS
(Proteintech, Manchester, UK), β-actin and α-tubulin (Sigma-Aldrich, Dorset, UK)
diluted as recommended in 5% milk/TBST or 5% BSA/TBST overnight at 4 °C with
agitation. Membranes were then washed in TBST for 4 × 10 min, and incubated
with horseradish peroxidase-conjugated secondary antibodies (Bio-Rad, Watford,
UK) diluted 1:3000 in 5% milk/TBST, or ﬂuorescently labelled secondary anti-
bodies for quantiﬁcation diluted 1:15,000 (Cell Signalling Technology, NEB,
Hitchin, UK), for 1 h at room temperature. Membranes were again washed for 4 ×
10 min in TBST. Detection was performed using Amersham ECL Western Blotting
Detection Reagent (GE Healthcare Life Sciences, Buckinghamshire, UK), Clarity
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Western ECL Substrate (Bio-Rad, Watford, UK) or Immobilon Western Chemi-
luminescent HRP Substrate (Merck Millipore, Watford, UK), X-ray ﬁlm and
Compact X4 ﬁlm developer (Xograph, Gloucestershire, UK). Quantiﬁcation of
ﬂuorescently labelled membranes was performed using the Odyssey infrared
imaging system (LI-COR, Cambridge, UK). Unless otherwise indicated, reagents
were from Sigma-Aldrich, Dorset, UK. Uncropped western blot images of Fig. 6a, e
are shown in Supplementary Data 2 and 3.
Absolute quantiﬁcation of MCL1 and BCL-XL. Cells seeded and cultured for 24 h
were lysed in RIPA lysis buffer and protein concentrations determined as above.
Colorectal and melanoma PDX tumour tissue was homogenised and protein
concentrations determined as described above. Recombinant protein standards for
MCL1 (Cloud-Clone Corp, Texas, USA) and BCL-XL (R&D Systems, Abingdon,
Oxfordshire, UK) were diluted in RIPA with 1 × Laemmli sample buffer to a
concentration range of 2.5–100 nM. SDS-PAGE was then performed with
5–6 standards of 0.0375 pmol to 1.5 pmol MCL1 or BCL-XL protein to determine
the levels of MCL1 and BCL-XL in 15 to 20 μg of total cellular protein by western
blotting with anti-MCL1 antibody (Santa Cruz Biotechnology, Dallas, USA; sc-819)
and anti-BCL-XL antibody (Cell Signalling Technology, NEB, Hitchin, UK; 2762)
and using anti-rabbit ﬂuorescently labelled secondary antibodies (Cell Signalling
Technology, NEB, Hitchin, UK) diluted 1:15,000 and infrared imaging for quan-
tiﬁcation (LI-COR, Cambridge, UK).
Immunoprecipitation. Cells were lysed in ice-cold TG lysis buffer (20 mM Tris-
HCl (pH 7.4), 137 mM NaCl, 1 mM EGTA, 1% (v/v) Triton X-100, 10% (v/v)
glycerol, 1.5 mM MgCl2, 50 mM NaF, 1 mM Na3VO4, 5 μg mL−1 aprotinin, 10 μg
mL−1 leupeptin, 1 mM PMSF), and incubated with 50 μL protein A-sepharose
beads (Sigma-Aldrich, Dorset, UK; bead slurry of 10 g resuspended in 40 mL PBS)
per mL of lysate for 30 min at 4 °C to preclear. At the same time 200 μL protein
A-sepharose beads were incubated in 750 μL TG lysis buffer with anti-BCL-XL
antibody (Cell Signalling Technology; 2762 or 2764) diluted 1:50, anti-MCL1
antibody diluted 1:25 (Cell Signalling Technology; 94296) or anti-MCL1 antibody
(Santa Cruz Biotechnology; sc-819) diluted 1:10 and incubated at 4 °C with rotation
for 1 h. Following preclearing, lysates were centrifuged at 13,000 × g at 4 °C for
10 min and supernatants transferred to fresh pre-chilled tubes to remove protein
A-sepharose beads and insoluble material. Lysates were then subjected to protein
assay using Bradford reagent in which 5 μL cleared lysate was mixed with 795 μL
ultra-pure water and 200 μL Bradford reagent (Bio-Rad Laboratories, Watford,
UK), and absorbance measured at 595 nm using a PHERAstar FS plate reader
(BMG Labtech, Aylesbury, UK). Seven hundred and ﬁfty microlitres of normalised
lysate were then added to washed protein A-sepharose beads bound to antibody
and incubated for 4 h at 4 °C with rotation. Residual lysate was retained as input
samples and prepared for SDS-PAGE by boiling for 5 min in 1 × Laemmli sample
buffer. Immunoprecipitate supernatants were retained for unbound supernatant
fraction analysis and boiled for 5 min in 1 × Laemmli sample buffer, while protein
A-sepharose beads harbouring immunoprecipitate were washed four times in TG
lysis buffer, resuspended in 1 × Laemmli sample buffer and boiled for 5 min.
Lysates were then subjected to SDS-PAGE and western blotting. For western
blotting of immunoprecipitates, the majority of primary antibodies were detected
using protein G–horseradish peroxidase (Bio-Rad Laboratories, Watford, UK), to
avoid heavy and light chain interference from the antibodies used in the immu-
noprecipitation reactions. Unless otherwise indicated, reagents were from Sigma-
Aldrich, Dorset, UK.
Colony formation assays. A375 cells were seeded in 12-well plates at 150 cells per
well, allowed to settle for 24 h and treated as indicated in the Figure legends.
Seventy-two hours later, cells were washed and the medium replaced with fresh
medium only without compounds. Seven days after initial treatment colonies were
ﬁxed with 3:1 (v/v) methanol/acetic acid, washed in water, stained with 0.1% (w/v)
crystal violet/PBS (Sigma-Aldrich, Dorset, UK) and counted using Adobe Photo-
shop (Adobe Systems Europe Ltd, Maidenhead, UK). Relative cell number was then
assessed by solubilising cells in 10% (v/v) acetic acid and measuring absorbance at
590 nm.
Cell cycle analysis by ﬂow cytometry. Following treatment as indicated in the
Figure legends, culture medium from cells growing on plates was collected,
adherent cells trypsinised and cells and media then recombined. Cells were pelleted
by centrifugation (400 × g, RT, 5 min) and resuspended in 0.2 mL PBS. Cells were
ﬁxed in 70% (v/v) ethanol/PBS at 4 °C for at least 30 min. Samples were then
centrifuged (400 × g, 4 °C, 5 min), washed with PBS, and resuspended in 0.25 mL
PBS containing 25 μg RNase A (Sigma-Aldrich, Dorset, UK) and 12.5 μg of the
DNA-intercalating agent propidium iodide (PI; Sigma-Aldrich, Dorset, UK). Fol-
lowing 30 min incubation at 37 °C, cell cycle proﬁles were acquired with an LSR II
ﬂow cytometer (BD Biosciences, Oxford, UK) to measure binding of PI to DNA,
and counting 10,000 cells per sample. Data was analysed using FlowJo (FlowJo
LLC, Oregon, USA) software package and sub-G1, G1, S and G2-M cell cycle
phases gated using the strategy shown in Supplementary Data 4.
Annexin V-DAPI staining and ﬂow cytometry. Following treatment as indicated
in the Figure legends, culture medium from cells growing on dishes was collected,
adherent cells trypsinised and cells and media then recombined. Cells were pelleted
by centrifugation (400 × g, RT, 5 min), resuspended in 1 mL PBS and then cen-
trifuged again before being washed further in 1 mL annexin V binding buffer
(10 mM HEPES/NaOH (pH 7.4), 140 mM NaCl, 2.5 mM CaCl2). Cells were then
resuspended in 0.2 mL annexin V binding buffer containing 1 μg mL−1 DAPI
(Sigma-Aldrich, Dorset, UK) and 0.1 μg mL−1 annexin V-FITC (BioLegend,
London, UK), and incubated for 10 min. Annexin V/DAPI staining was then
assessed using an LSR II ﬂow cytometer (BD Biosciences, Oxford, UK) and
counting 10,000 cells per sample. Data was analysed using FlowJo (FlowJo LLC,
Oregon, USA) software package to quantify annexin V and/or DAPI-positive cells
using the gating strategy shown in Supplementary Data 5.
BAX activation assay. Following treatment as indicated in the Figure legends,
culture medium from cells growing on plates was collected, adherent cells trypsi-
nised and cells and media then recombined. Cells were pelleted by centrifugation
(400 × g, 4 °C, 5 min) and then ﬁxed by resuspending in 1% (w/v) formaldehyde/
PBS (Sigma-Aldrich, Dorset, UK) for 10 min at room temperature. Cells were then
centrifuged (400 × g, 4 °C, 5 min), formaldehyde removed, and washed twice with
PBS. Cells were permeabilised in 0.1% (w/v) saponin/PBS (Sigma-Aldrich, Dorset,
UK) for 15 min at room temperature, washed once in PBS and then incubated with
10 μg mL−1 anti-BAX antibody (clone 6A7 speciﬁc for active BAX, BD Biosciences,
Oxford, UK) diluted in PBS for 30 min on ice. Control samples incubated in PBS
only (no primary anti-BAX antibody) were also included. Cells were washed three
times in PBS and then incubated with 10 μg mL−1 anti-mouse ﬂuorochrome-
conjugated secondary antibody (anti-mouse Alexa Fluor 488, Thermo Fisher Sci-
entiﬁc, Loughborough, UK) diluted in PBS for 30 min on ice. Following three
washes in PBS, cells were resuspended in 200 μL PBS and BAX activity assessed
using an LSR II ﬂow cytometer (BD Biosciences, Oxford, UK) and counting 10,000
cells per sample. Data was analysed using FlowJo (FlowJo LLC, Oregon, USA)
software package to quantify cells positive for active BAX under each condition
using the gating strategy shown in Supplementary Data 6.
Caspase activation assay. Cells were treated in 96-well plates as indicated in the
Figure legends and caspase activation determined using Caspase-Glo 3/7 Assay
(Promega, Southampton, UK) following the manufacturer’s instructions.
DNA sequencing analysis. Cells were cultured in their normal growth medium
containing PLX4720 and/or selumetinib as indicated in the Figure legends. Cell
pellets were prepared, and DNA extracted using an AllPrep DNA/RNA/miRNA
Universal Kit according to the manufacturer’s instructions, with an initial
QIAShredder step (Qiagen, Manchester, UK). Two-hundred and twenty-ﬁve
nanograms of puriﬁed genomic DNA was used for Next-Generation Sequencing
(NGS) library construction. Sequencing libraries with 241 genes were generated
using the HaloPlex Target Enrichment System for Illumina Sequencing Version
D.3 (Agilent Technologies, Stockport, UK), following the manufacturer’s protocol.
All libraries were visualised on the Agilent TapeStation 2200 prior to normalisation
and sequencing. Libraries were sequenced on the Illumina HiSeq 2500 System
using TruSeq SBS (sequencing by synthesis) reagents (Illumina, Eindhoven,
Netherlands).
Raw-sequencing reads were mapped to the human reference genome hg19
using BWA-MEM aligner algorithm57. The VarDict pairwise algorithm58 was used
to identify the signiﬁcance of variant changes (P-value and odds ratio from Fisher’s
exact test of allele frequency and depth) in resistant vs. parental cells. VarDict
default ﬁlters applied for variant quality, where a variant needed to pass in either
the parent or the resistant cell line. Signiﬁcantly different variants were prioritised
by removing variants with: P-value > 0.05 or odds ratio <1.5 and >0.66 for
comparison between parental and resistant samples; AF difference in both
directions <0.1; variant depth in both samples <100; PASS ﬂag in the VarDict
output not equal to TRUE or MAXRATE; silent mutations; SNPs; regions
downstream or upstream of genes, intergenic regions, introns, 3′- and 5′-UTRs.
The Seq2C algorithm (https://github.com/AstraZeneca-NGS/Seq2C) was used
to quantify gene level copy number changes. Depth of coverage was normalised to
remove assay variability (position-speciﬁc variation in depth). Copy number is
stated as a log2 difference in normalised depth to each of: all samples in this data set
(and all measured genes); all genes in the speciﬁc sample; the gene of interest in the
non-resistant sample. Copy events with log2 ratio change >3 were prioritised, and
assessed for supporting SNP-speciﬁc changes in variant depth looking for: multiple
SNPs to the gene showing coordinated grouping across samples; changes in depth
of some SNPs supporting the copy number change direction, while others remain
constant.
DNA sequencing data are available in the National Centre for Biotechnology
Information (NCBI) Sequence Read Archive (https://www.ncbi.nlm.nih.gov/sra)
under the project number PRJNA531927 [https://www.ncbi.nlm.nih.gov/bioproject/
PRJNA531927].
Statistical analyses. Results, unless otherwise indicated, are presented as mean ±
standard deviation (SD) and originate from at least three independent experiments.
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Statistical signiﬁcance was determined by two-tailed paired or unpaired t-test, two-
tailed Mann–Whitney test, one-way ANOVA, Kruskal–Wallis test, or two-way
ANOVA using GraphPad Prism 6 or 7. Multiple comparisons tests and adjust-
ments were applied as indicated. Signiﬁcance values were set at P > 0.05 (ns), P ≤
0.05 (*), P ≤ 0.01 (**), P ≤ 0.001 (***) or P ≤ 0.0001 (****). Where bar charts are
used, the individual data points have been overlaid, except in occasional cases
where this detrimentally affects the clarity of the data.
Data availability
The DNA sequencing data have been deposited in the NCBI Sequence Read Archive
(https://www.ncbi.nlm.nih.gov/sra) under the project number PRJNA531927 [https://
www.ncbi.nlm.nih.gov/bioproject/PRJNA531927]. All the other data supporting the
ﬁndings of this study are available within the article and Supplementary Information ﬁles
and from the corresponding author upon reasonable request. A reporting summary for
this article is available in the Supplementary Information.
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